Background--Recent studies have demonstrated a continuum in clinical risk related to mean pulmonary artery pressure that begins at >19 mm Hg, which is below the traditional threshold used to define pulmonary hypertension (PH) of 25 mm Hg. Because of the implications on patient diagnosis and prognosis, the generalizability and validity of these data need further confirmation.
T
here are accumulating data suggesting that the spectrum of clinical risk related to mean pulmonary artery pressure (mPAP) is wider than described originally. 1 Findings from 2 large right heart catheterization (RHC) registries 2, 3 and numerous other smaller clinical studies 4, 5 have demonstrated that mPAP of >19 mm Hg (previously termed "borderline pulmonary hypertension [PH]") is an independent risk factor for increased mortality. This observation indicates that the traditional mPAP threshold for defining PH of ≥25 mm Hg may be insufficient. This, in turn, has important potential implications for diagnosing and prognosticating patients with PH. Yet, the acceptance of a lower threshold of mPAP to identify patient populations at risk remains controversial, and formal assessment of published literature to determine a more precise estimate of risk across patient populations is lacking. Furthermore, the clinical relevance of mildly elevated PA pressure, measured by echocardiography, remains unclear. 6 Hence, the primary objective of this study was to perform a systematic review and meta-analysis of RHC and echocardiography studies to determine the association between mildly elevated PA pressures and mortality.
Methods Data Sources
We searched PubMed (MEDLINE), CINHAL, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials from inception through January 31, 2018, for Englishlanguage, peer-reviewed publications. The following keywords and Medical Subject Heading terms were used: "hypertension, pulmonary (Medical Subject Heading)," "pulmonary artery hypertension," "pulmonary arterial hypertension," "pulmonary artery pressure," "pulmonary arterial pressure," "pulmonary artery systolic pressure," "right ventricular systolic pressure," "mPAP," "mortality (Medical Subject Heading)," and "death (Medical Subject Heading)." Reference lists of systematic reviews, meta-analyses, and original studies identified by the electronic search were reviewed to find other potentially eligible studies. The authors declare that all supporting data are available within the article and references.
Study Selection
Studies were included in the meta-analysis if they:
(1) included a clearly defined or identifiable study group with mildly elevated PA pressure and (2) provided the number of events and/or risk estimates for mortality in the mild PH versus referent group. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-Analysis of Observational Studies in Epidemiology (MOOSE) checklists for the protocol of our meta-analysis.
7,8

Data Extraction and Quality Assessment
Three physician reviewers (D.K., S.L., and G.C.) evaluated independently study eligibility and quality, and performed data extraction using standardized data collection sheets. Disagreements were resolved by consensus. Study quality was evaluated using the Newcastle-Ottawa Scale, which assigns a star for 3 areas of study quality: selection (4 criteria), comparability (1 criterion), and outcome (3 criteria). 9 A study can be awarded a maximum of 1 star for each numbered criterion within the selection and outcome categories. A maximum of 2 stars can be given for comparability (Table 1) .
Exposure
The exposure was mild PH. Mild PH was defined as a lower limit mPAP of 19 to 21.5 mm Hg and an upper limit mPAP of %25 mm Hg, except some studies in which few patients (n=11 patients) with mPAP >25 mm Hg were also included in the mild PH group because of unavailability of mortality data 
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Study quality was evaluated using the Newcastle-Ottawa Scale, which assigns a star for 3 areas of study quality: selection (4 criteria), comparability (1 criterion), and outcome (3 criteria). A study can be awarded a maximum of 1 star for each numbered criterion within the selection and outcome categories. A maximum of 2 stars can be given for comparability. = criterion not satisfied (star not awarded) = criterion satisfied (star awarded)
Clinical Perspective
What Is New?
• Mildly elevated mean pulmonary artery pressure %19 to 24 mm Hg, which is below the traditional threshold of >25 mm Hg used to define pulmonary hypertension (PH), is associated with an increased risk of all-cause mortality.
• The association between mildly elevated mean pulmonary artery pressure and increased mortality is consistent when PA pressure is measured by right heart catheterization or estimated by echocardiography.
What Are the Clinical Implications?
• Our data support efforts to update the current definition of PH and affirm the reproducibility of mean pulmonary artery pressure >19 mm Hg as an appropriate and clinically accessible level distinguishing patients with PH from patients without PH.
• Acknowledging this would identify previously undiagnosed patients with PH and provide a framework in clinical practice by which to initiate careful monitoring and efforts to modify risk factors and improve outcomes. Continued separately for these patients (Table 2 ). For echocardiography studies that reported only the tricuspid regurgitation velocity or gradient (n=3), pulmonary artery systolic pressure (PASP) was calculated as tricuspid regurgitation gradient plus an assumed right atrial pressure of 5 mm Hg. This approach has been used in prior studies. 17, [20] [21] [22] mPAP was calculated using the following formula: (0.619PASP) + 2 mm Hg. 23 
Outcomes
The primary outcome of interest was all-cause mortality.
Statistical Analysis
Random-effects models of DerSimonian and Laird were used to calculate pooled risk ratio (RR) and corresponding 95% confidence interval (CI) for mortality. For studies that reported risk-adjusted time-to-event estimates (adjusted hazard ratio [HR] ) and the corresponding 95% CI, we performed secondary analyses using the generic inverse variance method to estimate pooled HR using a random-effects model. Secondary analyses were also performed using fixed-effect models. Heterogeneity was assessed using the Higgins I 2 statistic, with values <25% and >75% considered indicative of low and high heterogeneity, respectively. Pooled estimates were calculated for all studies as well as the a priori defined subgroups of echocardiography and RHC studies. Publication bias was assessed visually by asymmetry in funnel plots and formally using Egger's regression test and the Begg-Mazumdar rank correlation test. To assess the impact of publication bias on the risk estimate, we used Duval and Tweedie's Trim and Fill as well as cumulative meta-analysis (after sorting the included studies from largest to smallest size). 24, 25 All tests were 2 tailed, with a P<0.05 considered statistically significant. Analyses were performed using the Review Manager Version 5.3 (The Nordic Cochrane Center, The Cochrane Collaboration, 2014, Copenhagen, Denmark) and Comprehensive Meta-Analysis Version 3.0 (Biostat, Englewood, NJ).
Results
The database search yielded 11 184 articles. After removing duplicates, 7920 articles were screened at the title/abstract level and 7880 were excluded for various reasons (eg, systematic reviews, case reports, studies that included only patients with known PH, and studies with no data on mortality). Forty full-text articles were assessed for eligibility ( Figure 1 ). Fifteen (8 RHC and 7 echocardiography) studies were included in the meta-analysis. [2] [3] [4] [5] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] The characteristics of the included studies are shown in Table 2 . Of the 15 studies, 12 were retrospective, 1 was prospective, 1 was ambispective, and 1 was a post hoc analysis of a randomized There was evidence of publication bias on the basis of asymmetry in the funnel plot as well as results of the Egger's regression test and the Begg-Mazumdar rank correlation test ( Figure 6 ). However, the presence of publication bias did not influence the risk estimate and overall result (Duval and Tweedie's Trim and Fill adjusted RR, 1.34; 95% CI, 1.15-1.56) (Figure 7) . Similarly, cumulative meta-analysis demonstrated that the RR had stabilized with the inclusion of the larger studies and did not shift significantly with the addition of smaller studies, suggesting that the inclusion of smaller studies did not introduce bias (Figure 8 ).
Discussion
Data from this study address controversy on the mPAP level required to capture clinical risk in patients referred for RHC or Abramson et al 14 Kjaergaard et al 15 Shalaby et al 16 Lam et al 17 Damy et al 18 Cabrita et al 19 Choudhary et al 20 Ref.
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Ref. echocardiography using a meta-analysis, which is the optimal research tool for determining aggregate risk across study populations. 26 We report that mildly elevated PA pressures, estimated by either echocardiography or invasive catheterization, are associated with 19% increased risk of mortality over 5 years. Despite analyzing both community-based and referral populations with varying underlying comorbidities, there was only mild statistical heterogeneity of risk across the included studies. This suggests a truly generalizable association between mild PH and mortality. These data support the ongoing efforts to identify optimal cutoffs for hemodynamic parameters in PH, including pulmonary arterial hypertension, to identify at-risk populations earlier.
27
A notable finding of this study is the consistent association between mild PH and increased mortality when PA pressure was measured by either RHC or echocardiography. Although RHC is the only test available to diagnose PH, echocardiography is the preferred screening test for at-risk patients. 6 Current guidelines recommend further evaluation of patients for PH if the tricuspid regurgitation velocity is >2.9 m/s (corresponding to PASP >%40 mm Hg). 6 However, our findings demonstrate that PA pressure assessed by echocardiography, at levels considered currently to be below the range of clinical significance (tricuspid regurgitation velocity %>2.5 m/s, PASP >35 mm Hg) across both communitybased and referral populations, is, in fact, a valid predictor of mortality. Thus, our data suggest that when PA pressure can be measured by echocardiography, this is an effective screening tool for detecting patients at risk for mild PH who may benefit from further evaluation, close follow-up, and risk reduction interventions. 17, 20 Nonetheless, a recent study in patients with PH (mPAP >25 mm Hg) demonstrated modest correlation and poor agreement between echocardiographyderived and RHC-measured PASP and mPAP. 28 Fisher et al 29 showed that approximately half of the cases of PASP overestimation are related solely to right atrial pressure overestimation by echocardiography. Thus, although we used an assumed right atrial pressure of 5 mm Hg for calculating PASP in echocardiography studies that reported only tricuspid regurgitation velocity or gradient, concern for Figure 2 . Association between mild pulmonary hypertension (PH) and mortality (random-effects model). Studies included in this analysis are
Valerio et al, 10 Heresi et al, 11 Kovacs et al, 5 Suzuki et al, 12 Maron et al, 3 Takahashi et al, 13 Douschan et al, 4 Assad et al, 2 Abramson et al, misclassification remains when relying on echocardiography alone for the diagnosis of PH (or mild PH). Furthermore, the effect sizes of mild PH, as estimated by RHC and echocardiography on mortality, although different, are not directly comparable to suggest different clinical recommendations for patients with mild PH diagnosed via these 2 modalities. Our meta-analysis, together with findings from the individual studies analyzed, provides comprehensive evidence in support of defining PH in contemporary and clinically relevant terms. Specifically, these data affirm the reproducibility across selected and unselected populations for mPAP >19 mm Hg as an appropriate and clinically accessible level distinguishing patients with PH from patients without PH. Acknowledging this would identify previously undiagnosed patients with PH and provide a framework in clinical practice by which to initiate careful monitoring and efforts to modify risk factors. 30 These patients should also be considered for enrollment in ongoing and future PH clinical trials investigating pharmacological and nonpharmacological (eg, exercise program and weight loss) interventions to attenuate risk and improve outcomes in this population. Indeed, randomized controlled trials examining the efficacy and safety of established pulmonary artery hypertension therapies in patients with mild mPAP are already underway. 31 
Limitations
First, this is a meta-analysis of nonrandomized studies and has all limitations of observational data, including selection bias and unmeasured confounding variables. Second, restricted by the nature and characteristics of this metaanalysis, we did not have access to patient-level data. Therefore, we are unable to characterize covariates that modulate risk within the mild PH group, such as elevated pulmonary vascular resistance. This is a particularly important limitation, because the addition of pulmonary vascular resistance to analysis of cardiopulmonary hemodynamic data is needed to exclude mildly increased PA pressure that is Figure 3 . Association between mild pulmonary hypertension (PH) and mortality (fixed-effect model). Studies included in this analysis are
Valerio et al, 10 Heresi et al, 11 Kovacs et al, 5 Suzuki et al, 12 Maron et al, 3 Takahashi et al, 13 Douschan et al, 4 Assad et al, 2 Abramson et al, physiologic in the setting of increased cardiac output or cor pulmonale from a diagnosis of mild PH. Similarly, although we performed analysis using adjusted HRs, the precise impact of comorbidities cannot be readily assessed across studies in the absence of patient-level data. Third, the possibility that differences in cardiopulmonary comorbidities and not PA Figure 5 . Pooled hazard ratio for mortality using risk-adjusted time-to-event estimates (fixed-effect model). Studies included in this analysis are Heresi et al, 11 Suzuki et al, 12 Maron et al, 3 Takahashi et al, 13 Assad et al, 2 Shalaby et al, 16 Cabrita et al, 19 and Choudhary et al. 20 CI indicates confidence interval; PH, pulmonary hypertension; IV, Inverse Variance; RHC, right heart catheterization. Figure 4 . Pooled hazard ratio for mortality using risk-adjusted time-to-event estimates (random-effects model). Studies included in this analysis are Heresi et al, 11 Suzuki et al, 12 Maron et al, 3 Takahashi et al, 13 Assad et al, 2 Shalaby et al, 16 Cabrita et al, 19 and Choudhary et al. 20 CI indicates confidence interval; PH, pulmonary hypertension; IV, Inverse Variance; RHC, right heart catheterization.
pressure were responsible for differences in clinical outcome in this group cannot be excluded. However, pooled HRs derived from risk-adjusted time-to-event estimates demonstrated a 19% increased risk of mortality in patients with mild PH compared with the referent group. Fourth, the association of mild PH and mortality in the subgroups of patients with cardiac, pulmonary, hematologic, or connective tissue disease could not be determined because of unavailability of mortality data in these different subgroups. Last, the mortality estimates are based on an mPAP cutoff of %19 to 20 mm Hg that was selected from prior published data, although a lower cutoff may yield slightly different results.
Conclusion
In a meta-analysis of 15 nonrandomized studies, mild PH was associated with an increased risk of all-cause mortality compared with the referent group. This finding was consistent in the subgroups of RHC and echocardiography studies. These data add to the growing body of literature on the hemodynamic range and prognostic significance of mild PH. Overall, our data affirm efforts to update the current PH definition and provide definitive data in support of future clinical trials to improve outcome in this vulnerable patient subgroup.
Disclosures
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